JPMorgan starts Savara coverage with USD 12 target for Savara stock

Published on 10/08/2026 at 21:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter loss was USD 0.16 per share versus USD 0.14 expected. Savara stock costs EUR 4.33 on October 8, 2026 after EUR 4.37.

Key points in brief

JPMorgan initiated coverage of Savara with an Overweight rating and a USD 12.00 price target on October 7, 2026.
Savara reported a second-quarter 2026 loss of USD 0.16 per share versus USD 0.14 expected.
The FDA decision date for Molbreevi is November 22, 2026, while the next earnings date is November 5, 2026.
The Lang & Schwarz price was EUR 4.33 after-hours on October 8, 2026, versus a EUR 4.37 prior close.

SVRA, US8051111016, Illustration mit AI erstellt.

Savara (ISIN US8051111016) was trading at EUR 4.33 at Lang & Schwarz on October 8, 2026 at 9:05 p.m. CEST, down 0.92 percent versus the prior close of EUR 4.37. On October 7, 2026, Markets Insider reported that JPMorgan initiated coverage with an Overweight rating and a USD 12.00 price target.

Three dates shape the story

On April 15, 2026, the FDA extended the Molbreevi review period by three months to November 22, 2026, according to RTTNews. The regulatory timetable is the central near-term milestone for Savara's inhaled molgramostim program in autoimmune pulmonary alveolar proteinosis.

On August 11, 2026, Savara reported a second-quarter loss of USD 0.16 per share, compared with a USD 0.14 expected loss, MarketBeat reported. The USD 0.02 per-share shortfall gives the new analyst coverage a counterweight: the valuation depends heavily on regulatory execution rather than current earnings.

On October 7, 2026, JPMorgan set its USD 12.00 target and an Overweight rating, according to Markets Insider. MarketBeat reported an average analyst target of USD 10.25, leaving JPMorgan's target USD 1.75 above that average.

What does the FDA date mean?

The November 22, 2026 decision date creates a defined test for the investment case. JPMorgan's USD 12.00 target and the USD 10.25 average target cited by MarketBeat both point to expectations centered on Molbreevi's regulatory path, while the second-quarter loss shows that commercial earnings have not yet replaced development risk.

Two dates remain ahead

The next earnings date is November 5, 2026, according to Makkler. The FDA decision on Molbreevi is scheduled for November 22, 2026, according to RTTNews.

SVRA price stays below its prior close

After-hours at Lang & Schwarz on October 8, 2026, Savara was trading at EUR 4.33, down 0.92 percent versus the EUR 4.37 prior close. The company is listed on Nasdaq under ticker SVRA, with a 52-week range of USD 3.35 to USD 7.01 and market capitalization of USD 997.0 million as of October 8, 2026. The further course of trading is shown by the continuously updated real-time quote of Savara stock.